Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- AML digital therapeutic lands Breakthrough Device Designation from FDAon January 17, 2022 at 8:09 am
Blue Note Therapeutics has announced the status has been granted to BNT200, a device to treat anxiety and depression in acute myeloid leukemia patients.
- Global Acute Myeloid Leukaemia Pipeline Landscape Report 2021 - Comprehensive Insights for Approx 150+ Companies and 150+ Pipeline Drugs - ResearchAndon January 17, 2022 at 2:58 am
The "Acute Myeloid Leukaemia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This "Acute myeloid leukaemia - Pipeline Insight, 2021" report provides ...
- Researchers highlight potential new therapeutic approach for leukemiaon January 16, 2022 at 2:06 am
A recent clinical study found that Acute myeloid leukaemia AML cells rely on a previously little-known protein called SCP4 for survival ...
- Popular Erie bowler, recovering from leukemia, excited to compete in Times-News Openon January 14, 2022 at 4:17 am
Philip J. Harris has undergone extensive treatment for leukemia since April 2021. He's now strong and healthy enough to bowl in the Times-News Open.
- Promising New Regimens for Treating Acute Myeloid Leukemiaon January 12, 2022 at 3:00 pm
Alice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.
- Fighting leukemia by targeting a little-known proteinon January 12, 2022 at 10:29 am
Proteins known as phosphatases are essential to myriad cellular signaling pathways, including those that drive cancer. A research team led by scientists at Cold Spring Harbor Laboratory has just ...
- Obscure protein is spotlighted in fight against leukemiaon January 11, 2022 at 2:29 pm
Acute myeloid leukemia (AML) is a cancer of white blood cells. Researchers discovered that AML cancer cells depend on a protein called SCP4 to survive. They think the previously little-known protein ...
- FDA grants breakthrough device designation to BNT200 for anxiety in acute myeloid leukemiaon January 11, 2022 at 8:10 am
The FDA granted breakthrough device designation to BNT200.BNT200 (Blue Note Therapeutics) is a digital therapeutic designed to treat anxiety and depressive symptoms among adults with acute myeloid ...
- Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemiaon January 6, 2022 at 1:08 pm
Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U.S. Food and Drug Administration (FDA) ...
- Actinium Pharma collaborates with EpicentRx to develop therapy for acute myeloid leukemiaon January 5, 2022 at 4:01 am
Actinium Pharmaceuticals (ATNM) and San Diego-based EpicentRx have entered into a research collaboration to study Actinium's Actimab-A targeted radiotherapy in combination ...
via Bing News